Recent Updates
Recently added Catalysts
RARE

Ultragenyx to Present Phase 3 Data for Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7 (MPS 7) at 14th International Symposium on MPS and Related Diseases

Key Takeaway: Ultragenyx to Present Phase 3 Data for Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7 (MPS 7) at 14th International Symposium on MPS and Related Diseases

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia

Full Press Release Details

Ultragenyx to Present Phase 3 Data for Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7 (MPS 7) at 14th International Symposium on MPS and Related Diseases.
Last updated: Jul 13, 2016